Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.95 |
| ▸ | POLB | P06746 | 3/20 | 0.95 |
| ▸ | GLS | O94925 | 5/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14986945 | 0.97 | ALDH1A1 (1.00) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL15709879 | 0.97 | ALDH1A1 (1.00) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL14977428 | 0.95 | ALDH1A1 (0.86) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL17402474 | 0.91 | ALDH1A1 (0.79) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL11412602 | 0.89 | ALDH1A1 (0.96) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL7321598 | 0.89 | ALDH1A1 (0.76) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL10952704 | 0.89 | ALDH1A1 (0.76) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL1968819 | 0.88 | ALDH1A1 (0.88) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL23016888 | 0.87 | ALDH1A1 (1.00) | ALDH1A1POLBGLSL3MBTL1GAA | |
| SCHEMBL11425081 | 0.87 | ALDH1A1 (1.00) | ALDH1A1POLBGLSL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603217-B1 | NOVEL 6,7-DISUBSTITUTED-ISOQUINOLINE DERIVATIVES AND THEIR USE | MONTISERA LTD (FI) | 2015-04-08 | — | — | EP | claimed |
| US-8815898-B2 | 6,7-disubstituted-sioquinoline derivatives and their use | MONTISERA LTD (FI) | 2014-08-26 | — | — | US | claimed |
| US-20130137719-A1 | Novel 6,7-disubstituted-sioquinoline derivatives and their use | MONTISERA LTD (FI) | 2013-05-30 | — | — | US | claimed |
| WO-2023022430-A1 | NOVEL MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AUTOIMMUNE DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-02-23 | — | — | WO | disclosed |
| WO-2023022430-A1 | NOVEL MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER OR AUTOIMMUNE DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-02-23 | — | — | WO | disclosed |
| CN-108785305-B | Heterocyclic inhibitors of glutaminase | 卡利泰拉生物科技公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | CALITHERA BIOSCIENCES INC. | 2020-05-28 | — | — | US | disclosed |
| EP-3620162-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | Calithera Biosciences Inc. (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-104220070-B | Heterocyclic inhibitors of glutaminase | 卡利泰拉生物科技公司 | 2020-01-21 | — | — | CN | disclosed |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. | 2019-10-17 | — | — | US | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8604016-B2 | Heterocyclic inhibitors of glutaminase | CALITHERA BIOSCIENCES INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078123-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | CALITHERA BIOSCIENCES INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-20130137719-A1 | Novel 6,7-disubstituted-sioquinoline derivatives and their use | MONTISERA LTD (FI) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140050699-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | ALDH1A1 639/4885POLB 2684/4885GLS 1/4885 |
| US-20190315733-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | ALDH1A1 639/4885POLB 2684/4885GLS 1/4885 |
| US-20200165238-A1 | Heterocyclic Inhibitors of Glutaminase | GLS, GLS2, GLUL | ALDH1A1 639/4885POLB 2684/4885GLS 1/4885 |
| US-20130137719-A1 | Novel 6,7-disubstituted-sioquinoline derivatives and their use | OPRM1, OPRK1, SULT2A1 | ALDH1A1 285/4885POLB 2825/4885GLS 492/4885 |
| US-20130157998-A1 | HETEROCYCLIC INHIBITORS OF GLUTAMINASE | GLS, GLS2, GLUL | ALDH1A1 639/4885POLB 2684/4885GLS 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.